On behalf of the PRECOMBAT Investigators

Slides:



Advertisements
Similar presentations
Is this the “spioenkop” for CABG?
Advertisements

Introduction Recent guidelines considered PCI to be a potential alternative to CABG for ULMCA stenosis, based on several large registries and randomized.
Seung-Jung Park, MD, PhD On behalf of the PRECOMBAT Investigators Professor of Medicine, University of Ulsan College of Medicine, Heart Institute, Asan.
CPORT- E Trial Randomized trial comparing outcomes of non-primary PCI at hospitals with and without on-site cardiac surgery.
Arterial Revascularization Therapies Part II: a non- randomized comparison of contemporary PCI and coronary artery bypass grafting (CABG) in patients with.
The Synergy between Percutaneous Coronary Intervention with TAXUS and Cardiac Surgery: The SYNTAX Study One Year Results of the PCI and CABG Registries.
Endeavor Safety: Pooled Analysis of Early and Late Safety of a Zotarolimus-Eluting Stent Laura Mauri, MD, MSc Brigham and Women’s Hospital Harvard Clinical.
Samsung Medical Center Cardiac & Vascular Center Young Bin Song, Joo-Yong Hahn, Seung-Hyuk Choi, Jin-Ho Choi, Sang Hoon Lee, Myung-Ho Jeong, Hyo-Soo Kim,
Effect of Intravascular Ultrasound- Guided vs. Angiography-Guided Everolimus-Eluting Stent Implantation: the IVUS-XPL Randomized Clinical Trial Myeong-Ki.
Columbia University Medical Center Cardiovascular Research Foundation New York City, NY Akiko Maehara, MD Use of IVUS Reduces Stent Thrombosis and Myocardial.
Prof. Dr. Sigmund Silber, FESC, FACC On behalf of the RESOLUTE
Disclosure Statement of Financial Interest
De Novo and Restenotic Coronary Lesions
Disclosure Statement of Financial Interest
Disclosures Runlin Gao has received a research grant
Ajay J. Kirtane, MD I have no real or apparent conflicts of interest to report.
Runlin Gao, M.D. On behalf of ABSORB China Investigators
Debate: Prophylactic Support Increases Risk With Little Benefit
Final Five-Year Follow-up of the SYNTAX Trial: Optimal Revascularization Strategy in Patients With Three-Vessel Disease and/or Left Main Disease Patrick.
Non-Inferiority Exposed: Uses and Abuses
Damian Gimpel Waikato Cardiothoracic Unit Journal Club
Washington Hospital Center, Division of Cardiology
Acute and Mid-Term Outcomes of Coronary Stent Implantation for the Treatment of Unprotected Left Main Coronary Artery Disease Dr mahmoud ebrahimi Dr hosein.
LONG-DES II Trial Randomized Comparison of the Efficacy of Sirolimus-Eluting Stent Versus Paclitaxel-Eluting Stent in the Treatment of Long Native Coronary.
DKCRUSH V Shao-Liang Chen, MD DKCRUSH V
The DKCRUSH-V Randomized Trial
Comprehensive Meta-Analysis of DES vs
Crossing CTOs via Planned Dissection: LaST (Limited Antegrade Subintimal Tracking): from knuckle wire to Bridgepoint Craig A. Thompson, M.D., MMSc. Director,
Vladimir Ganyukov, MD, PhD
Debate: What Does the Future Hold for the Treatment of Unprotected Left Main Disease? More PCI No More Routine Surgery Ron Waksman, MD, FACC Washington.
EXCELLA Studies - Novolimus Elution from PLLA Polymer Coated Stents DESyne® and DESyne BD: Design Specifications and Clinical Updates Stefan Verheye,
Crossing CTOs via Planned Dissection: LaST (Limited Antegrade Subintimal Tracking): from knuckle wire to Bridgepoint Craig A. Thompson, M.D., MMSc. Director,
On behalf of J. Belardi, M. Leon, L. Mauri,
Thomas Stiermaier, MD; Suzanne de Waha, MD;
Three Years Follow Up. SORT OUT II
Long-term follow-up of the DIABETES I (DIABETes and sirolimus Eluting Stent) trial: P Jiménez-Quevedo, M Sabaté, DJ Angiolillo, JA Gómez-Hospital, R Hernández-Antolín,
CIT 2018 Template Title 40 pt Bold Arial
CIT 2018 Template Title 40 pt Bold Arial
Giuseppe Biondi Zoccai, MD
CIT 2017 Template Title 40 pt Bold Arial
3-Year Clinical Outcomes From the RESOLUTE US Study
Comparison of Everolimus- and Biolimus-Eluting Coronary Stents With Everolimus-Eluting Bioresorbable Vascular Scaffolds: 2-year Outcomes of the EVERBIO.
Efficacy of Xience/Promus versus Cypher to rEduce Late Loss in stENT
Five-Year Cumulative Rates of Clinical Events after Cypher™ Stent Implantation: Insights from a Patient-Level Pooled Analysis of Four Randomized Trials.
CIT 2018 Template Title 40 pt Bold Arial
The Synergy between Percutaneous Coronary Intervention with TAXUS and Cardiac Surgery: The SYNTAX Study One Year Results of the PCI and CABG Registries.
Large-Scale Registry Examining Safety and Effectiveness of Zotarolimus-Eluting and Sirolimus-Eluting Stents in Patients with Coronary Artery Disease Western.
CIT 2017 Template Title 40 pt Bold Arial
Impact of Platelet Reactivity Following Clopidogrel Administration
CIT 2017 Template Title 40 pt Bold Arial
Incidence and management of restenosis after treatment of unprotected left main disease with drug-eluting stents: 70 restenotic cases from a cohort of.
On behalf of all principal COMPARE II investigators:
Five-Year Outcomes after Randomization to Transcatheter or Surgical Aortic Valve Replacement: Final Results of The PARTNER 1 Trial Michael J. Mack, MD.
Comprehensive Meta-Analysis of DES vs
CIT 2017 Template Title 40 pt Bold Arial
Gregg W. Stone, MD Columbia University Medical Center
The Synergy between Percutaneous Coronary Intervention with TAXUS and Cardiac Surgery: The SYNTAX Study One Year Results of the PCI and CABG Registries.
Presented at TCT 2006.
Martin B. Leon, David R. Holmes, Dean J. Kereiakes, Jeffrey J
Maintenance of Long-Term Clinical Benefit with
DEScover: One-Year Clinical Results
ISAR-LEFT MAIN: A Randomized Clinical Trial on Drug-Eluting Stents for Unprotected Left Main Lesions J. Mehilli, MD Deutsches Herzzentrum Technische.
ISAR-LEFT MAIN: A Randomized Clinical Trial on Drug-Eluting Stents for Unprotected Left Main Lesions J. Mehilli, MD Deutsches Herzzentrum Technische.
Ahmed A. Khattab, MD For the German Cypher Registry Investigators
Title 40pt Trebuchet MS Bold
ISAR-LEFT MAIN 2 Randomized Trial Zotarolimus- vs
Atlantic Cardiovascular Patient Outcomes Research Team
The American College of Cardiology Presented by Dr. A. Abazid
ISAR-LEFT MAIN 2 Randomized Trial Zotarolimus- vs
CIT 2018 Template Title 40 pt Bold Arial
Presentation transcript:

On behalf of the PRECOMBAT Investigators Premier of Randomized Comparison of Bypass Surgery versus Angioplasty Using Sirolimus-Eluting Stent in Patients with Left Main Coronary Artery Disease PRECOMBAT Trial Seung-Jung Park, MD, PhD On behalf of the PRECOMBAT Investigators Professor of Medicine, University of Ulsan College of Medicine, Heart Institute, Asan Medical Center, Seoul, Korea

Disclosure Statement of Financial Interest Researchfunds from the CardioVascular Research Foundation, Seoul, Korea, Cordis, Johnson and Johnson, Miami Lakes, Florida, and Health 21 R&D Project, Ministry of Health & Welfare, Korea, (#0412-CR02-0704-0001)

Introduction Recent registry and substudy results have shown that percutaneous coronary intervention (PCI) is safe and effective in patients with unprotected left main coronary artery (ULMCA) stenosis. However, due to the lack of randomized clinical trials, the comparability of PCI with coronary artery bypass graft (CABG) remains uncertain. This is the Bulleted List slide. To create this particular slide, click the NEW SLIDE button on your toolbar and choose the BULLETED LIST format. (Top row, second from left) The Sub-Heading and footnote will not appear when you insert a new slide. If you need either one, copy and paste it from the sample slide. If you choose not to use a Sub-Heading, let us know when you hand in your presentation for clean-up and we’ll adjust where the bullets begin on your master page. Also, be sure to insert the presentation title onto the BULLETED LISTMASTER as follows: Choose View / Master / Slide Master from your menu. Select the text at the bottom of the slide and type in a short version of your presentation title. Click the SLIDE VIEW button in the lower left hand part of your screen to return to the slide show. (Small white rectangle) 2

PRECOMBAT Trial Design DESIGN: a prospective, open-label, randomized trial OBJECTIVE: To compare PCI with sirolimus-eluting stents and CABG surgery for optimal revascularization of patients with ULMCA stenosis. PRINCIPAL INVESTIGATOR Seung-Jung Park, MD, PhD, Asan Medical Center, Seoul, Korea

Patient Flow EnrolledPatients (N=1454) Randomized Cohort N=600 CABG registry N=335 PCI registry N=475 Medication registry N=44 Assigned CABG N=300 Assigned PCI N=300 1-year follow-up CABG registry N=310 PCI registry N=457 Medication registry N=41 Treated CABG N=248 Treated PCI N=51 Treated medical N=1 Treated CABG N=24 Treated PCI N=276 Treated medical N=0 2-year follow-up CABG registry N=259 PCI registry N=289 Medication registry N=39 1-year follow-up N=296 1-year follow-up N=298 2-year follow-up N=266 2-year F/U N=270

Major Inclusion Criteria  18 years of age. Significant de novo ULMCA stenosis (>50%) Left main lesion and lesions outside ULMCA (if present) potentially comparably treatable with PCI and CABG, determined by physician and operators Objective evidence of ischemia or ischemic symptom with angina or NSTEMI This is the Bulleted List slide. To create this particular slide, click the NEW SLIDE button on your toolbar and choose the BULLETED LIST format. (Top row, second from left) The Sub-Heading and footnote will not appear when you insert a new slide. If you need either one, copy and paste it from the sample slide. If you choose not to use a Sub-Heading, let us know when you hand in your presentation for clean-up and we’ll adjust where the bullets begin on your master page. Also, be sure to insert the presentation title onto the BULLETED LISTMASTER as follows: Choose View / Master / Slide Master from your menu. Select the text at the bottom of the slide and type in a short version of your presentation title. Click the SLIDE VIEW button in the lower left hand part of your screen to return to the slide show. (Small white rectangle) 5

Major Exclusion Criteria Any contraindication to dual antiplatelet therapy Any previous PCI within 1 year Previous CABG Chronic total occlusion > 1 AMI within 1 week Shock or LV EF < 30% Planed surgery Disabled stroke Other comorbidity, such as CRF, liver disease, etc This is the Bulleted List slide. To create this particular slide, click the NEW SLIDE button on your toolbar and choose the BULLETED LIST format. (Top row, second from left) The Sub-Heading and footnote will not appear when you insert a new slide. If you need either one, copy and paste it from the sample slide. If you choose not to use a Sub-Heading, let us know when you hand in your presentation for clean-up and we’ll adjust where the bullets begin on your master page. Also, be sure to insert the presentation title onto the BULLETED LISTMASTER as follows: Choose View / Master / Slide Master from your menu. Select the text at the bottom of the slide and type in a short version of your presentation title. Click the SLIDE VIEW button in the lower left hand part of your screen to return to the slide show. (Small white rectangle) 6

Study Procedures Sirolimus-eluting Cypher stent for all lesions Strong recommendation of IVUS-guidance Other adjunctive devices at the operator’s discretion Use of LIMA to LAD anastomosis Off- or on-pump surgery at the operator’s discretion Dual antiplatelet therapy at least for 6 months after PCI Standard medical treatment after PCI and CABG This is the Bulleted List slide. To create this particular slide, click the NEW SLIDE button on your toolbar and choose the BULLETED LIST format. (Top row, second from left) The Sub-Heading and footnote will not appear when you insert a new slide. If you need either one, copy and paste it from the sample slide. If you choose not to use a Sub-Heading, let us know when you hand in your presentation for clean-up and we’ll adjust where the bullets begin on your master page. Also, be sure to insert the presentation title onto the BULLETED LISTMASTER as follows: Choose View / Master / Slide Master from your menu. Select the text at the bottom of the slide and type in a short version of your presentation title. Click the SLIDE VIEW button in the lower left hand part of your screen to return to the slide show. (Small white rectangle) 7

Follow-up Clinical follow-up at 30 days and 6, 9, and 12 months via clinic visit or telephone interview. Routine angiographic follow-up at 8-10 months after PCI. Ischemia-guided angiographic follow-up after CABG. Retrospective SYNTAX score measurement in the Core Lab, CVRF, Seoul, Korea This is the Bulleted List slide. To create this particular slide, click the NEW SLIDE button on your toolbar and choose the BULLETED LIST format. (Top row, second from left) The Sub-Heading and footnote will not appear when you insert a new slide. If you need either one, copy and paste it from the sample slide. If you choose not to use a Sub-Heading, let us know when you hand in your presentation for clean-up and we’ll adjust where the bullets begin on your master page. Also, be sure to insert the presentation title onto the BULLETED LISTMASTER as follows: Choose View / Master / Slide Master from your menu. Select the text at the bottom of the slide and type in a short version of your presentation title. Click the SLIDE VIEW button in the lower left hand part of your screen to return to the slide show. (Small white rectangle) 8

Primary End Point A composite of major adverse cardiac or cerebrovascular events (MACCE) for the 12-month period after randomization including Death from any cause Myocardial infarction (MI) Stroke Ischemia-driven target vessel revascularization (TVR) This is the Bulleted List slide. To create this particular slide, click the NEW SLIDE button on your toolbar and choose the BULLETED LIST format. (Top row, second from left) The Sub-Heading and footnote will not appear when you insert a new slide. If you need either one, copy and paste it from the sample slide. If you choose not to use a Sub-Heading, let us know when you hand in your presentation for clean-up and we’ll adjust where the bullets begin on your master page. Also, be sure to insert the presentation title onto the BULLETED LISTMASTER as follows: Choose View / Master / Slide Master from your menu. Select the text at the bottom of the slide and type in a short version of your presentation title. Click the SLIDE VIEW button in the lower left hand part of your screen to return to the slide show. (Small white rectangle) 9

Definition MI Within 48 hours: new Q waves AND CK-MB  5 times After 48 hours: new Q waves OR CK-MB > 1 time plus ischemic symptoms or signs Stroke: confirmed by imaging studies and neurologist TVR Ischemia-driven: ischemic symptom, sign OR angiographic stenosis> 70% Clinical-driven: ischemia symptom or sign This is the Bulleted List slide. To create this particular slide, click the NEW SLIDE button on your toolbar and choose the BULLETED LIST format. (Top row, second from left) The Sub-Heading and footnote will not appear when you insert a new slide. If you need either one, copy and paste it from the sample slide. If you choose not to use a Sub-Heading, let us know when you hand in your presentation for clean-up and we’ll adjust where the bullets begin on your master page. Also, be sure to insert the presentation title onto the BULLETED LISTMASTER as follows: Choose View / Master / Slide Master from your menu. Select the text at the bottom of the slide and type in a short version of your presentation title. Click the SLIDE VIEW button in the lower left hand part of your screen to return to the slide show. (Small white rectangle) 10

Power Calculation Assumed primary end point of 1-year MACCE in the CABG group : 13%. A noninferiority margin : 7% A one-sided type I error rate : 0.05 Power : 80% Assumption : a total of 572 patients (286 per group) A final sample size : 600 patients (300 per group) assuming 5% of loss This is the Bulleted List slide. To create this particular slide, click the NEW SLIDE button on your toolbar and choose the BULLETED LIST format. (Top row, second from left) The Sub-Heading and footnote will not appear when you insert a new slide. If you need either one, copy and paste it from the sample slide. If you choose not to use a Sub-Heading, let us know when you hand in your presentation for clean-up and we’ll adjust where the bullets begin on your master page. Also, be sure to insert the presentation title onto the BULLETED LISTMASTER as follows: Choose View / Master / Slide Master from your menu. Select the text at the bottom of the slide and type in a short version of your presentation title. Click the SLIDE VIEW button in the lower left hand part of your screen to return to the slide show. (Small white rectangle) 11

Statistical Analysis Kaplan-Meier method to estimate survivals with comparison using log-rank test. Noninferiority test using the Z-test with 95% CI of difference in the 1-year MACCE rate. Survival analyses to 2 years because the MACCE rate at 1 year did not reach the anticipated level. Subgroups analysis using the Cox regression model with tests for interaction. Primary analysis in intention-to-treat peinciple This is the Bulleted List slide. To create this particular slide, click the NEW SLIDE button on your toolbar and choose the BULLETED LIST format. (Top row, second from left) The Sub-Heading and footnote will not appear when you insert a new slide. If you need either one, copy and paste it from the sample slide. If you choose not to use a Sub-Heading, let us know when you hand in your presentation for clean-up and we’ll adjust where the bullets begin on your master page. Also, be sure to insert the presentation title onto the BULLETED LISTMASTER as follows: Choose View / Master / Slide Master from your menu. Select the text at the bottom of the slide and type in a short version of your presentation title. Click the SLIDE VIEW button in the lower left hand part of your screen to return to the slide show. (Small white rectangle) 12

Baseline Clinical Characteristics PCI (N=300) CABG P value Age, years 61.8±10.0 62.7±9.5 0.24 Male sex 228 (76.0) 231 (77.0) 0.77 Body mass index 24.6±2.7 24.5±3.0 0.74 Medically treated diabetes Any 102 (34.0) 90 (30.0) 0.29 Requiring insulin 10 (3.3) 9 (3.0) 0.82 Hypertension 163 (54.3) 154 (51.3) 0.46 Hyperlipidemia 127 (42.3) 120 (40.0) 0.56 Current smoker 89 (29.7) 83 (27.7) 0.59 Previous PCI 38 (12.7) 1.0 Previous myocardial infarction 13 (4.3) 20 (6.7) 0.21 Previous congestive heart failure 0 (0) 2 (0.7) 0.16 This is the Bulleted List slide. To create this particular slide, click the NEW SLIDE button on your toolbar and choose the BULLETED LIST format. (Top row, second from left) The Sub-Heading and footnote will not appear when you insert a new slide. If you need either one, copy and paste it from the sample slide. If you choose not to use a Sub-Heading, let us know when you hand in your presentation for clean-up and we’ll adjust where the bullets begin on your master page. Also, be sure to insert the presentation title onto the BULLETED LISTMASTER as follows: Choose View / Master / Slide Master from your menu. Select the text at the bottom of the slide and type in a short version of your presentation title. Click the SLIDE VIEW button in the lower left hand part of your screen to return to the slide show. (Small white rectangle) 13

Baseline Clinical Characteristics PCI (N=300) CABG P value Chronic renal failure 4 (1.3) 1( 0.3) 0.37 Peripheral vascular disease 15 (5.0) 7 (2.3) 0.08 Chronic pulmonary disease 6 (2.0) 10 (3.3) 0.31 Clinical manifestation 0.12 Stable angina or asymptomatic 160 (53.3) 137 (45.7) Unstable angina 128 (42.7) 144 (48.0) Recent acute myocardial infarction 12 (4.0) 19 (6.3) Ejection fraction, % 61.7±8.3 60.6±8.5 EuroSCORE value 2.6±1.8 2.8±1.9 0.16 Electrocardiographic findings 0.77 Sinus rhythm 286 (96.6) 289 (97.3) Atrial fibrillation 5 (1.7) Others 3 (1.0) This is the Bulleted List slide. To create this particular slide, click the NEW SLIDE button on your toolbar and choose the BULLETED LIST format. (Top row, second from left) The Sub-Heading and footnote will not appear when you insert a new slide. If you need either one, copy and paste it from the sample slide. If you choose not to use a Sub-Heading, let us know when you hand in your presentation for clean-up and we’ll adjust where the bullets begin on your master page. Also, be sure to insert the presentation title onto the BULLETED LISTMASTER as follows: Choose View / Master / Slide Master from your menu. Select the text at the bottom of the slide and type in a short version of your presentation title. Click the SLIDE VIEW button in the lower left hand part of your screen to return to the slide show. (Small white rectangle) 14

Baseline Angiographic Characteristics PCI (N=300) CABG P value Extent of disease vessel 0.68 LM only 27 (9.0) 34 (11.3) LM plus 1-vessel 50 (16.7) 53 (17.7) LM plus 2-vessel 101 (33.7) 90 (30.0) LM plus 3-vessel 122 (40.7) 123 (41.0) Bifurcation left main involvement 200 (66.9) 183 (62.2) 0.24 Diameter stenosis of left main, % 0.12  50 and  70 160 (53.3) 141 (47.0)  70 140 (46.7) 159 (53.0) Right coronary artery disease 149 (49.7) 0.41 Restenotic lesion 1 (0.3) 2 (0.7) 0.56 Chronic total occlusion 1.0 SYNTAX score 24.4±9.4 25.8±10.5 0.09 This is the Bulleted List slide. To create this particular slide, click the NEW SLIDE button on your toolbar and choose the BULLETED LIST format. (Top row, second from left) The Sub-Heading and footnote will not appear when you insert a new slide. If you need either one, copy and paste it from the sample slide. If you choose not to use a Sub-Heading, let us know when you hand in your presentation for clean-up and we’ll adjust where the bullets begin on your master page. Also, be sure to insert the presentation title onto the BULLETED LISTMASTER as follows: Choose View / Master / Slide Master from your menu. Select the text at the bottom of the slide and type in a short version of your presentation title. Click the SLIDE VIEW button in the lower left hand part of your screen to return to the slide show. (Small white rectangle) 15

Procedural Characteristics PCI (N=300) CABG (N=300) Stents number in LM 1.6±0.8 Stent length in LM, mm 44.0±31.9 Stents per pt 2.7±1.4 Stent length per pt, mm 60.0±42.1 IVUS guidance 250 (91.2) Bifurcation treatment 1-stent technique 87 (46.3) 2-stent technique Crush 33 (17.9) Kissing T stent 25 (13.6) V stent 4 (2.2) Others 2 (1.1) Final kissing balloon 129 (70.1) Grafts per patient 2.7±0.9 Arterial grafts 2.1±0.9 Vein graft 0.7±0.8 Use of LIMA 233 (93.6) Off-pump surgery 155 (63.8) This is the Bulleted List slide. To create this particular slide, click the NEW SLIDE button on your toolbar and choose the BULLETED LIST format. (Top row, second from left) The Sub-Heading and footnote will not appear when you insert a new slide. If you need either one, copy and paste it from the sample slide. If you choose not to use a Sub-Heading, let us know when you hand in your presentation for clean-up and we’ll adjust where the bullets begin on your master page. Also, be sure to insert the presentation title onto the BULLETED LISTMASTER as follows: Choose View / Master / Slide Master from your menu. Select the text at the bottom of the slide and type in a short version of your presentation title. Click the SLIDE VIEW button in the lower left hand part of your screen to return to the slide show. (Small white rectangle) PCI CABG P Complete revascularization 205 (68.3) 211 (70.3) 0.60 16

Primary End Point of MACCE PCI CABG Non-inferiority p= 0.001 8.7 12.2 6.7 8.1 p=0.39 p=0.12 This is the Bulleted List slide. To create this particular slide, click the NEW SLIDE button on your toolbar and choose the BULLETED LIST format. (Top row, second from left) The Sub-Heading and footnote will not appear when you insert a new slide. If you need either one, copy and paste it from the sample slide. If you choose not to use a Sub-Heading, let us know when you hand in your presentation for clean-up and we’ll adjust where the bullets begin on your master page. Also, be sure to insert the presentation title onto the BULLETED LISTMASTER as follows: Choose View / Master / Slide Master from your menu. Select the text at the bottom of the slide and type in a short version of your presentation title. Click the SLIDE VIEW button in the lower left hand part of your screen to return to the slide show. (Small white rectangle) 17

Noninferiority Test for Primary End Point of 1-Year MACCE 1-year MACCE rate CABG: 6.7% PCI: 8.7% Prespecified non-inferiority margin: 7% -2 -1 1 2 3 4 5 6 7 8 9 10 Difference, 2% 95% CI, -1.6 to 5.6% Non-inferiority p= 0.001 This is the Bulleted List slide. To create this particular slide, click the NEW SLIDE button on your toolbar and choose the BULLETED LIST format. (Top row, second from left) The Sub-Heading and footnote will not appear when you insert a new slide. If you need either one, copy and paste it from the sample slide. If you choose not to use a Sub-Heading, let us know when you hand in your presentation for clean-up and we’ll adjust where the bullets begin on your master page. Also, be sure to insert the presentation title onto the BULLETED LISTMASTER as follows: Choose View / Master / Slide Master from your menu. Select the text at the bottom of the slide and type in a short version of your presentation title. Click the SLIDE VIEW button in the lower left hand part of your screen to return to the slide show. (Small white rectangle) Difference (%) of 1-year MACCE rate between (PCI – CABG) 95% CI 18

Death, MI or Stroke PCI CABG p=0.66 p=0.83 4.7 4.0 4.4 3.3 This is the Bulleted List slide. To create this particular slide, click the NEW SLIDE button on your toolbar and choose the BULLETED LIST format. (Top row, second from left) The Sub-Heading and footnote will not appear when you insert a new slide. If you need either one, copy and paste it from the sample slide. If you choose not to use a Sub-Heading, let us know when you hand in your presentation for clean-up and we’ll adjust where the bullets begin on your master page. Also, be sure to insert the presentation title onto the BULLETED LISTMASTER as follows: Choose View / Master / Slide Master from your menu. Select the text at the bottom of the slide and type in a short version of your presentation title. Click the SLIDE VIEW button in the lower left hand part of your screen to return to the slide show. (Small white rectangle) 19

Death PCI CABG p=0.58 p=0.45 This is the Bulleted List slide. To create this particular slide, click the NEW SLIDE button on your toolbar and choose the BULLETED LIST format. (Top row, second from left) The Sub-Heading and footnote will not appear when you insert a new slide. If you need either one, copy and paste it from the sample slide. If you choose not to use a Sub-Heading, let us know when you hand in your presentation for clean-up and we’ll adjust where the bullets begin on your master page. Also, be sure to insert the presentation title onto the BULLETED LISTMASTER as follows: Choose View / Master / Slide Master from your menu. Select the text at the bottom of the slide and type in a short version of your presentation title. Click the SLIDE VIEW button in the lower left hand part of your screen to return to the slide show. (Small white rectangle) 20

Cardiac Death PCI CABG p=0.31 p=0.13 This is the Bulleted List slide. To create this particular slide, click the NEW SLIDE button on your toolbar and choose the BULLETED LIST format. (Top row, second from left) The Sub-Heading and footnote will not appear when you insert a new slide. If you need either one, copy and paste it from the sample slide. If you choose not to use a Sub-Heading, let us know when you hand in your presentation for clean-up and we’ll adjust where the bullets begin on your master page. Also, be sure to insert the presentation title onto the BULLETED LISTMASTER as follows: Choose View / Master / Slide Master from your menu. Select the text at the bottom of the slide and type in a short version of your presentation title. Click the SLIDE VIEW button in the lower left hand part of your screen to return to the slide show. (Small white rectangle) 21

Myocardial Infarction PCI CABG p=0.71 p=0.48 This is the Bulleted List slide. To create this particular slide, click the NEW SLIDE button on your toolbar and choose the BULLETED LIST format. (Top row, second from left) The Sub-Heading and footnote will not appear when you insert a new slide. If you need either one, copy and paste it from the sample slide. If you choose not to use a Sub-Heading, let us know when you hand in your presentation for clean-up and we’ll adjust where the bullets begin on your master page. Also, be sure to insert the presentation title onto the BULLETED LISTMASTER as follows: Choose View / Master / Slide Master from your menu. Select the text at the bottom of the slide and type in a short version of your presentation title. Click the SLIDE VIEW button in the lower left hand part of your screen to return to the slide show. (Small white rectangle) 22

Stroke PCI CABG p=0.15 p=0.55 This is the Bulleted List slide. To create this particular slide, click the NEW SLIDE button on your toolbar and choose the BULLETED LIST format. (Top row, second from left) The Sub-Heading and footnote will not appear when you insert a new slide. If you need either one, copy and paste it from the sample slide. If you choose not to use a Sub-Heading, let us know when you hand in your presentation for clean-up and we’ll adjust where the bullets begin on your master page. Also, be sure to insert the presentation title onto the BULLETED LISTMASTER as follows: Choose View / Master / Slide Master from your menu. Select the text at the bottom of the slide and type in a short version of your presentation title. Click the SLIDE VIEW button in the lower left hand part of your screen to return to the slide show. (Small white rectangle) 23

Ischemia-Driven TVR PCI CABG p=0.13 p=0.022 This is the Bulleted List slide. To create this particular slide, click the NEW SLIDE button on your toolbar and choose the BULLETED LIST format. (Top row, second from left) The Sub-Heading and footnote will not appear when you insert a new slide. If you need either one, copy and paste it from the sample slide. If you choose not to use a Sub-Heading, let us know when you hand in your presentation for clean-up and we’ll adjust where the bullets begin on your master page. Also, be sure to insert the presentation title onto the BULLETED LISTMASTER as follows: Choose View / Master / Slide Master from your menu. Select the text at the bottom of the slide and type in a short version of your presentation title. Click the SLIDE VIEW button in the lower left hand part of your screen to return to the slide show. (Small white rectangle) 24

Symptomatic Graft Occlusion & Stent Thrombosis to 2 Years CABG (n=300) PCI (n=300) P=0.18 Patients (%) 1.4% SYNTAX 3-Year Report_Randomized_12JUL10.doc exhibits 21 0.3% PCI CABG Post-procedure; ITT population

Subgroup Analysis This is the Bulleted List slide. To create this particular slide, click the NEW SLIDE button on your toolbar and choose the BULLETED LIST format. (Top row, second from left) The Sub-Heading and footnote will not appear when you insert a new slide. If you need either one, copy and paste it from the sample slide. If you choose not to use a Sub-Heading, let us know when you hand in your presentation for clean-up and we’ll adjust where the bullets begin on your master page. Also, be sure to insert the presentation title onto the BULLETED LISTMASTER as follows: Choose View / Master / Slide Master from your menu. Select the text at the bottom of the slide and type in a short version of your presentation title. Click the SLIDE VIEW button in the lower left hand part of your screen to return to the slide show. (Small white rectangle) 26

Conclusion The PRECOMBAT randomized trial suggests that PCI with sirolimus-eluting stent appears a potential alternative to CABG with a noninferior incidence of 2-year MACCE for patients with ULMCA stenosis. This is the Bulleted List slide. To create this particular slide, click the NEW SLIDE button on your toolbar and choose the BULLETED LIST format. (Top row, second from left) The Sub-Heading and footnote will not appear when you insert a new slide. If you need either one, copy and paste it from the sample slide. If you choose not to use a Sub-Heading, let us know when you hand in your presentation for clean-up and we’ll adjust where the bullets begin on your master page. Also, be sure to insert the presentation title onto the BULLETED LISTMASTER as follows: Choose View / Master / Slide Master from your menu. Select the text at the bottom of the slide and type in a short version of your presentation title. Click the SLIDE VIEW button in the lower left hand part of your screen to return to the slide show. (Small white rectangle) 27